The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) is holding a public workshop on September 25, 2009 in Rockville, MD to discuss strategies for educating the public about the phase-out of chlorofluorocarbon (CFC)-propelled over-the-counter (OTC) epinephrine inhalers from the US market. The one day workshop will solicit input from key stakeholders in the asthma community, the pharmaceutical industry, experts in health care communication, and the public about how best to alert patients and transition them to therapeutic alternatives.
For more information, please visit: Epinephrine
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO FDA (1-888-463-6332) or (301) 796-3400 from 8:00 am - 4:30 pm Monday - Friday. You can also email us at druginfo@xxxxxxxxxxx.
For additional drug information, please visit the DDI Web page: (http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm082585.htm.)
For up-to-date drug information, follow the FDA’s Division of Drug Information on Twitter: FDA_Drug_Info
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420
